FDA approves Eli Lilly oral weight loss pill Foundayo for daily use

U.S. regulators have cleared a new oral option in the fast-growing weight-loss drug market. The U.S. Food and Drug Administration (FDA) on Wednesday approved Foundayo, a once-daily tablet for weight loss made by Eli Lilly. Officials said the medicine, also known as orforglipron, works by mimicking a natural hormone involved in appetite regulation.

What happened: The approval places Foundayo among a limited set of GLP-1 medicines available as pills. It is described as the second GLP-1 drug in tablet form to reach the market, following Novo Nordisk’s Wegovy, which was approved in December. The decision adds another choice in a treatment category that has expanded as more people seek therapies for obesity and related health complications.

How Eli Lilly is positioning the product: The company said Foundayo is intended as an alternative to injectable GLP-1 treatments. Eli Lilly stated that a pill format could improve accessibility for people who prefer tablets or face practical barriers to injections, including those who are reluctant to use needles or who struggle to start or stay on injectable regimens.

Rollout plan and distribution: Eli Lilly said distribution will begin through its direct-to-consumer channel. The company announced Foundayo will be available via LillyDirect starting Monday, with wider availability through pharmacies and telehealth services expected shortly after. The approach underscores how drugmakers are using multiple routes, including online channels and remote-care pathways, to reach patients.

Pricing and coverage questions: Launch information outlined a tiered price structure for uninsured patients, with an initial monthly cost of about $149 and higher strengths priced up to $349. The company’s pricing and channel strategy arrives as payers and governments increase scrutiny of affordability and insurance coverage for weight-loss medicines.

What it means: Coverage decisions could change what patients pay out of pocket. Information provided indicated Medicare coverage for certain eligible patients could begin as early as this summer. Separately, under a proposal from the Trump administration, copayments could potentially be reduced to $50 per month for eligible patients, if applied.

Competition and global relevance: Foundayo’s entry is expected to sharpen competition in the GLP-1 market, where manufacturers are trying to broaden patient reach and distinguish products through delivery methods and access. The source material notes that U.S. regulatory approvals often shape commercial planning, cross-border demand preparation, and the pace at which similar oral options are pursued in other major healthcare systems globally.

Uncertainties remain: Despite FDA approval, open questions include how quickly broader pharmacy and telehealth access will arrive and how fast coverage pathways—such as Medicare for certain patients—translate into real-world availability for individuals.